Renji Cognitive Team Releases the First Domestic and International Recommendations for Sequential-like Management of Anti-Aβ Monoclonal Antibody Therapy in Alzheimer’s Disease (IMAGE)
Caption
With the increasing clinical use of anti-amyloid-β monoclonal antibodies in Alzheimer’s disease in China, some patients have completed or are approaching the predefined treatment period, leading to emerging clinical questions regarding post-treatment maintenance, discontinuation, monitoring, and retreatment. However, no consensus has yet been established on long-term management or sequential-like treatment strategies after anti-amyloid-β monoclonal antibody therapy. Based on current clinical evidence and the practical experience of Renji Cognitive Center, this article proposes an experience-based protocol for sequential-like management of anti-amyloid-β monoclonal antibody therapy. The protocol uses amyloid PET-derived Centiloid values as the core objective reference and recommends stratified management according to clinical clearance status and prior amyloid clearance rate. This protocol is intended to provide a clinical reference and requires further validation and optimization through real-world studies and long-term follow-up.
Credit
GENG Jieli, ZHI Nan, SONG Yaying, CAO Wenwei, WANG Liling, XIAO Jinwen, LI Haixia, JI Chenhui, WANG Jintao, LI Jianping, LI Shuang, HU Yiying, MIN Shurui, ZHANG Bei, WANG Hualong, WANG Gang.
Usage Restrictions
Credit must be given to the creator. Only noncommercial uses of the work are permitted. No derivatives or adaptations of the work are permitted.
License
CC BY-NC-ND